Daniel Passeri - Sep 30, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Sep 30, 2021
Transactions value $
-$461,534
Form type
4
Date filed
10/8/2021, 04:00 PM
Previous filing
Sep 27, 2021
Next filing
Mar 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise +75K +135.44% 130K Sep 30, 2021 Direct F1
transaction CUE Common Stock Tax liability -$462K -31.7K -24.3% $14.57 98.7K Sep 30, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Restricted Stock Units Options Exercise $0 -75K -50% $0.00 75K Sep 30, 2021 Common Stock 75K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Each restricted stock unit award represents a contingent right to receive one share of common stock.
F3 One half of the Restricted Stock Units vested on September 30, 2021 and the balance will vest on March 31, 2022.